RESUMEN
Wound infusion with local anesthetics has been used for postoperative pain relief with variable results. This randomized, controlled, double-blind clinical trial examines the effect of ropivacaine infusion on pain after laparoscopic cholecystectomy. A total of 110 patients were randomly assigned to 2 groups. After induction of anesthesia a 75-mm catheter was inserted subcutaneously and connected to an elastomeric pump containing either 0.75% ropivacaine (ropivacaine group) or normal saline (control group) for 24 hours postoperatively. Before skin closure, each hole was infiltrated with 2 mL of 0.75% ropivacaine or normal saline according to randomization. Pain at rest, pain during cough, and analgesic consumption were recorded in the postanesthesia care unit and at 2, 4, 8, 24, and 48 hours postoperatively. Analgesic requirements and pain scores were recorded 1 and 3 months after surgery. The ropivacaine group reported less pain during cough (P=0.044) in the postanesthesia care unit (P=0.017) and 4 hours postoperatively (P=0.038). Ropivacaine wound infusion had no effect on late and chronic pain.
Asunto(s)
Amidas/administración & dosificación , Anestésicos Locales/administración & dosificación , Colecistectomía Laparoscópica/métodos , Dolor Postoperatorio/prevención & control , Acetaminofén/uso terapéutico , Adulto , Anciano , Analgésicos no Narcóticos/uso terapéutico , Analgésicos Opioides/uso terapéutico , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Infusiones Intralesiones , Infusiones Subcutáneas , Cuidados Intraoperatorios , Masculino , Persona de Mediana Edad , Tempo Operativo , Dimensión del Dolor , Cuidados Posoperatorios , Ropivacaína , Tramadol/uso terapéuticoRESUMEN
BACKGROUND: We investigated a possible effect of ondansetron on the duration of sensory and motor block produced by ropivacaine. METHODS: Fifty male patients undergoing transurethral surgery received either 8 mg oral ondansetron the evening before surgery plus IV 8 mg ondansetron 15 min before subarachnoid anesthesia or placebo. All patients received 2.2 mL of 0.75% plain ropivacaine intrathecally. Sensory and motor block were assessed 30 min after the intrathecal injection and every 30 min thereafter until recovery from the motor block. RESULTS: Thirty minutes after spinal injection of ropivacaine, we first measured, in both groups, the time to maximum block for both sensory and motor modalities. The maximum level of the sensory block, defined as decreased sensation, was T8 in the control and T6 in the ondansetron group, and absence of sensation was defined as T11 and T9 for the control and the ondansetron groups, respectively. Regarding block duration, 180 min after spinal injection, sensory block was detected in 11 of 22 and 16 of 24 patients and motor block in 1 of 22 and 0 of 24 in the control and ondansetron groups, respectively. Sensory and motor block did not differ between groups at any measured time point. CONCLUSIONS: Ondansetron had no effect on the subarachnoid sensory or motor block produced by ropivacaine.
Asunto(s)
Amidas/administración & dosificación , Anestesia Raquidea , Anestésicos Locales/administración & dosificación , Antieméticos/administración & dosificación , Bloqueo Nervioso/métodos , Ondansetrón/administración & dosificación , Medicación Preanestésica , Administración Oral , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Interacciones Farmacológicas , Humanos , Inyecciones Intravenosas , Inyecciones Espinales , Masculino , Persona de Mediana Edad , Umbral del Dolor/efectos de los fármacos , Ropivacaína , Factores de Tiempo , Procedimientos Quirúrgicos Urológicos MasculinosRESUMEN
BACKGROUND: Gabapentin is an adjuvant analgesic and may enhance the spread of subarachnoid block. We investigated the effects of pretreatment with gabapentin on subarachnoid block characteristics and hemodynamics. METHODS: Seventy patients undergoing transurethral procedures under subarachnoid anesthesia with 2.2 mL of 0.75% ropivacaine were randomly assigned to receive preoperatively 400 mg of gabapentin 6 hourly, up to a total dose of 1200 mg, or placebo. Sensory and motor blocks were assessed every 30 min until regression of sensory block to L4. At the same time intervals, systolic and diastolic arterial blood pressures and heart rate were recorded. RESULTS: There were no differences between groups in the sensory block levels or degree of motor block. Sensory block 150 min after the subarachnoid injection had regressed to L4 in 26 of 32 patients in the gabapentin group and in 25 of the 33 patients in the control group. Systolic arterial blood pressure was decreased in the gabapentin group (P = 0.002 for the main effect of group, and P = 0.03 at 60 min between the groups). The diastolic arterial blood pressure did not differ between the groups, but overall, the heart rate was more rapid in the gabapentin group (P = 0.002, but only for baseline values between the groups, P = 0.036). CONCLUSION: Pretreatment with gabapentin had no effect on the spread of sensory block or the regression of motor block but was associated with lower systolic arterial blood pressure values in patients undergoing subarachnoid anesthesia with ropivacaine.
Asunto(s)
Amidas , Aminas/uso terapéutico , Analgésicos/uso terapéutico , Anestésicos Locales , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Hemodinámica/efectos de los fármacos , Bloqueo Nervioso , Umbral Sensorial/efectos de los fármacos , Espacio Subaracnoideo , Ácido gamma-Aminobutírico/uso terapéutico , Administración Oral , Anciano , Aminas/administración & dosificación , Analgésicos/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Ácidos Ciclohexanocarboxílicos/administración & dosificación , Gabapentina , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Persona de Mediana Edad , Papiloma/cirugía , Cuidados Preoperatorios , Ropivacaína , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/cirugía , Ácido gamma-Aminobutírico/administración & dosificaciónRESUMEN
In this prospective randomized, double-blind study, we investigated the effect of ondansetron on the lidocaine subarachnoid block. Fifty-four male patients scheduled for transurethral surgery under subarachnoid anesthesia received oral ondansetron 4 mg the evening before surgery and 4 mg IV 15 min before subarachnoid anesthesia (ondansetron group) or placebo (placebo group). Two milliliters of 5% hyperbaric lidocaine was administered intrathecally. Sensory block was assessed 20, 25, and 30 min and motor block 30, 60, and 90 min after lidocaine injection. In two patients in the control group and five in the ondansetron group, sensory block was not assessed for technical reasons. In the ondansetron group, sensory block values differed significantly over the 30-min period of assessments (P = 0.048). Fifteen, 20, 25, and 30 min after subarachnoid lidocaine, the level of sensory block was at T11, T12, T12, and T12 in the control group and T12, T12, T12, and L1 in the ondansetron group and differed between groups at 30 min (P = 0.019). Motor block did not differ between the two groups at any study time. We conclude that, under the conditions of our study, ondansetron antagonizes the sensory block produced by lidocaine.